Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes.

@article{vonMinckwitz2012DefinitionAI,
  title={Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes.},
  author={Gunter von Minckwitz and Michael Untch and Jens-Uwe Blohmer and Serban D. Costa and Holger Eidtmann and Peter Andreas Fasching and Bernd Gerber and Wolfgang Eiermann and J{\"o}rn Hilfrich and Jens Huober and Christian Jackisch and Manfred Kaufmann and Gottfried E. Konecny and Carsten Denkert and Valentina Nekljudova and Keyur M Mehta and Sibylle Loibl},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2012},
  volume={30 15},
  pages={
          1796-804
        }
}
  • G. von MinckwitzM. Untch S. Loibl
  • Published 20 May 2012
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
PURPOSE The exact definition of pathologic complete response (pCR) and its prognostic impact on survival in intrinsic breast cancer subtypes is uncertain. [] Key MethodRESULTS Disease-free survival (DFS) was significantly superior in patients with no invasive and no in situ residuals in breast or nodes (n = 955) compared with patients with residual ductal carcinoma in situ only (n = 309), no invasive residuals in breast but involved nodes (n = 186), only focal-invasive disease in the breast (n = 478), and…

Figures and Tables from this paper

Impact of pathologic complete response on survival after neoadjuvant chemotherapy in early-stage breast cancer: a population-based analysis

The cumulative data support pCR as a valid surrogate endpoint in both clinical trials and population-based settings and shows a similar but non-statistically significant trend was seen in the HER-2-positive and ER + subtypes.

Clinical Outcomes Among Major Breast Cancer Subtypes After Neoadjuvant Chemotherapy: Impact on Breast Cancer Recurrence and Survival

Achieving pCR after NAC is related with significantly better DFS, with the potential of maximized breast and axillary conservation based on clinical response, and the distribution of expertise in a cross-disciplinary setting could provide safe and favourable prognosis, while improving cosmetic outcomes and quality of life.

Predictive Factors and Value of ypN+ after Neoadjuvant Chemotherapy in Clinically Lymph Node-Negative Breast Cancer

The prognosis of clinically lymph node negative breast cancer depended on ypN+, which was associated with ypTinv and luminal subtype, and y pN+ was the only significant poor prognostic factor for OS.

Lymphovascular invasion can be better than pathologic complete response to predict prognosis in breast cancer treated with neoadjuvant chemotherapy

LVI more than pCR in surgical breast cancer specimens obtained after NAC was a significant independent prognostic factor and it is suggested that patients with hormone receptor-negative cancer and LVI should receive short-term follow-up and appropriate management.

Assessment of pathologic response and long-term outcome in locally advanced breast cancers after neoadjuvant chemotherapy: comparison of pathologic classification systems

The results suggest that pathologic classification systems that evaluate residual tumors in both breast and lymph nodes after NAC show better association with clinical outcome and combining LVI with other classic prognostic factors might have prognostic value for the assessment of treatment response after Nac.

Association between Pathological Complete Response and Outcome Following Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer Patients

The pCR rate following neoadjuvant chemotherapy for breast cancer in Thai women attending the authors' institution was 11.7%; pCR was more frequently observed in HER2 and triple-negative breast tumor subtypes.

Molecular subtypes in advanced breast cancer respond differently to neoadjuvant chemotherapy : assessment of complete pathologic response and prognosis

The study confirms that pCR was the favorable prognostic factor in OS in three molecular subtypes in patients with locally advanced breast cancer after receiving neoadjuvant chemotherapy with epirubicin and sequential docetaxel and indicates that the molecular mechanisms of susceptibility to NC vary between these two groups.

Prognostic significance of pathological complete response following neoadjuvant chemotherapy for operable breast cancer

The aim of the present retrospective study was to ascertain the significance of pathological complete response (pCR) on overall survival (OS) and disease-free survival (DFS) in each disease subtype
...

References

SHOWING 1-10 OF 41 REFERENCES

Residual ductal carcinoma in situ in patients with complete eradication of invasive breast cancer after neoadjuvant chemotherapy does not adversely affect patient outcome.

Residual DCIS in patients who experience complete eradication of the invasive cancer in the breast and lymph nodes does not adversely affect survival or local recurrence rate, and inclusion of patients with residual DC IS in the definition of pCR is justified when this outcome is used as an early surrogate for long-term survival.

Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy.

Residual cancer burden was calculated as a continuous index combining pathologic measurements of primary tumor and nodal metastases and was a significant predictor of distant relapse-free survival (DRFS) in multivariate Cox regression analyses.

Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer.

  • C. LiedtkeC. Mazouni L. Pusztai
  • Medicine, Biology
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2008
Patients with TNBC have increased pCR rates compared with non-TNBC, and those with pCR have excellent survival, however, patients with RD after neoadjuvant chemotherapy have significantly worse survival if they have TNBC compared with other patients, particularly in the first 3 years.

Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy.

Neoadjuvant chemotherapy has the capacity to completely clear the breast and axillary lymph nodes of invasive tumor before surgery and patients with LABC who have a pCR in the breastand axillary nodes have a significantly improved disease-free survival rate.

Effect of preoperative chemotherapy on the outcome of women with operable breast cancer.

  • B. FisherJ. Bryant H. Bear
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 1998
Preoperative chemotherapy is as effective as postoperative chemotherapy, permits more lumpectomies, is appropriate for the treatment of certain patients with stages I and II disease, and can be used to study breast cancer biology.

Impact of treatment characteristics on response of different breast cancer phenotypes: pooled analysis of the German neo-adjuvant chemotherapy trials

Dosing characteristics appear important for successful treatment of breast cancer, and longer treatment, higher cumulative doses of anthracyclines and taxanes, and the addition of capecitabine and trastuzumab are associated with better response.

Incidence and prognostic significance of complete axillary downstaging after primary chemotherapy in breast cancer patients with T1 to T3 tumors and cytologically proven axillary metastatic lymph nodes.

  • R. RouzierJ. Extra E. Bourstyn
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2002
It is suggested that axillary status is a better prognostic factor than response of the primary tumor to primary chemotherapy in breast cancer patients treated with primary chemotherapy.

Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups.

  • M. UntchP. Fasching S. Loibl
  • Medicine, Biology
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2011
Neoadjuvant combination of trastuzumab and chemotherapy resulted in a high pCR rate in HER2-overexpressing primary breast cancer, and patients with a pCR after neoadjuant anti-HER2 therapy in combination with chemotherapy followed by maintenance trastzumab have an improved long-term outcome.

[Histologic regression of breast cancer after primary (neoadjuvant) chemotherapy].

The aim of this study was to evaluate the improvement of operability objectively and to correlate the histology of the primary tumour with the response to treatment, with invasive lobular carcinomas particularly resistant to primary chemotherapy.

Intensified neoadjuvant chemotherapy in early-responding breast cancer: phase III randomized GeparTrio study.

Patients receiving eight TAC cycles had statistically significantly higher sonographic response rates but not pathological complete response rates than those receiving six TACcycles, however, they also had more toxic effects.